AstraZeneca's Combination Inhaler Shines In Phase 3 Asthma Trial

  • AstraZeneca Plc AZN posted full results from the positive MANDALA Phase 3 trial of PT027, an albuterol/budesonide fixed-dose combination rescue medication in patients with asthma.
  • The data exhibited that PT027 at two different strengths of budesonide demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue.
  • Compared with albuterol rescue, PT027 at the 180mcg albuterol/160mcg budesonide dose reduced the risk of a severe exacerbation by 27%.
  • In secondary endpoints, PT027 (180mcg albuterol/160mcg budesonide) demonstrated a 33% reduction in mean annualized total systemic corticosteroid exposure and a 24% reduction in annualized severe exacerbation rate.
  • A numerically higher odds of patients experienced improved symptom control and quality of life after 24 weeks of treatment with PT027 than albuterol rescue.
  • PT027 at a lower budesonide dose (180mcg albuterol/80mcg budesonide) also demonstrated a statistically significant reduction of 17% in the risk of severe exacerbation versus albuterol rescue.
  • Price Action: AZN shares are up 1.97% at $64.39 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!